Black Diamond Therapeutics, Inc.

46 articles with Black Diamond Therapeutics, Inc.

• 

  Clinical Catch-Up: May 17-21

  5/24/2021

  It was another busy week for clinical trial announcement. Here’s a look.

• Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

  5/19/2021

  Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions

• Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial

  5/17/2021

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that it will host a webcast presentation on Wednesday, May 19, 2021 at 6:00 PM ET to discuss pharmacokinetic, safety, and preliminary efficacy data from the Phase 1

• Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/7/2021

  Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initial Phase 1 clinical pharmacokinetic (PK), safety, and preliminary efficacy data to be presented at American Society of Clinical Oncology (ASCO) Annual Meeting

• Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

  4/28/2021

  Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented

• Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

  4/10/2021

  Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research Annual Meeting, taking place April 9-14, 2021.

• Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/25/2021

  Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initiation of safety expansion cohort anticipated in the second quarter of 2021 with start of Phase 2 portion planned for second half of 2021 BDTX-1535, a brain-penetrant MasterKey inhibitor of EGFR mutations for glioblastoma multiforme (GBM) and solid tumors

• Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

  3/10/2021

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on BDTX-189 and BDTX-1535 will be presented as late-breaking poster presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place April 10-15, 2021.

• Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

  3/2/2021

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data from two programs emerging from the Company’s proprietary MAP platform targeting BRAF and fibroblast growth factor receptor (FGFR) at the European Society of Medical Oncology Targeted Anticancer Therapies

• Black Diamond Therapeutics to Present at Upcoming Investor Conferences

  2/23/2021

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences: The Cowen 41 st Annual Virtual Health Care Conference.

• Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series

  2/11/2021

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present at the BMO Biopharma Spotlight Series on Thursday, February 18, 2021 at 11:50 AM ET.

• Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference

  1/5/2021

  Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the J.P. Morgan 39th Annual Virtual Healthcare Conference on Tuesday, January 12, 2021 at 7:30 AM ET.

• Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Piper Sandler 32 nd Annual Virtual Healthcare Conference, taking place December 1-3, 2020. A webcast of the p

• Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

  11/20/2020

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), as well as the commencement of Investigational New Drug (IND)-enabling studies.

• Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference

  11/11/2020

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 2:40 PM GMT/9:40 AM ET.

• Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/10/2020

  Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 Strengthened Board of Directors with appointment of Robert A. Ingram as Chairman Bolstered executive team with appointment of Rachel Humphrey, M.D., as Chief Medical Officer Cash, cash equivalents, and investments of $333.1 million as of September 30, 2020, expected to be sufficient to fund operations into 2023

• Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

  10/26/2020

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data on the Company’s lead product candidate BDTX-189 at the 32 nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020). “These pre-clinical data demonstrate BDTX-189’s abi

• Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

  10/12/2020

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on the Company’s lead product candidate BDTX-189 will be presented at the 32 nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) taking place October 24-25, 2020. Presentation de

• 

  BioSpace Movers & Shakers, Oct. 2

  10/2/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board

  9/29/2020

  - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Robert A. Ingram as the Chairman of its Board of Directors. Brad Bolzon, Ph.D., Chairman and Managing Director at Versant Ventures and Black Diamond’s founding Chairman, will remain on the Company’s board. “As we welcome B